Back to MPLN Home Client Services: +1 865.380.9746

ETV6::RUNX1 t(12;21)

Test ID: F ETV6::RUNX1/t(12;21) CPT Code: 88374 (if automated read), 88377 (if manual read)
Expected Turnaround Time
5 days
Stated turn-around-times (TATs) are for clinical use only and subject to change based on biopharma protocol requirements. Final TATs will be specified in the biopharma study contract.
Clinical Information
FISH test on hematologic specimens for detection of ETV6::RUNX1 (also known as TEL::AML1) gene fusion. This fusion, associated with t(12;21), is the most frequent genetic abnormality in childhood B-acute lymphoblastic leukemia (ALL) found in 20-30% of cases. Cytogenetically, the t(12;21) is a subtle abnormality and not easily detected with conventional cytogenetic banding techniques.
Requisition Forms
Oncology Pathology Requisition

Specimen Requirements

Specimen Requirements
  • Whole Blood: 5 mL, EDTA preferred (NaHep accepted)
  • Bone Marrow Aspirate: 3 mL, EDTA preferred (NaHep accepted)
Specimen Stability

72 hours

Storage Requirements
  • Whole Blood: 2°C to 25°C
  • Bone Marrow Aspirate: 2°C to 25°C
  • Fixed Cytogenetically Prepared Cells: -28°C to -15°C
Shipping Conditions
Ambient, Refrigerated
Shipping Recommendations

AMBIENT, Use a refrigerated (NOT FROZEN) gel pack in the shipment to protect from extreme temperatures. Separate gel pack from specimen. Do not freeze.

Specimen Rejection Criteria

Clotted specimen; Specimen exposed to extreme temperature; Anticoagulant toxic to cells; Insufficient number of cells

Test Details

Synonyms

t(12;21)(p13;q22), ETV6/RUNX1, TEL::AML1

Keywords
Fluorescence in-situ Hybridization, Leukemia, Oncology, Oncology FISH Probes, Acute Lymphoblastic Leukemia (ALL)
Test Method
Fluorescence in situ hybridization (FISH)
Methodology Category
FISH
Regulatory Status
ASR
Special Considerations

All attempts will be made to process and report samples received > 72 hours post-collection.  Bone marrow is the sample of choice in most heme malignancies.

Associations

Pediatric acute lymphoblastic leukemia, Acute lymphoblastic leukemia (ALL)